OPKO Health to Announce 2016 Fourth Quarter Financial Results on March 1, 2017
February 27 2017 - 4:15PM
OPKO Health, Inc. (NASDAQ:OPK), a multinational
biopharmaceutical and diagnostics company, will announce operating
and financial results for the fourth quarter ended December
31, 2016 after the close of the U.S. financial markets on
Wednesday, March 1, 2017.
OPKO’s senior management will provide a business update and
discuss its financial results in a conference call and live audio
webcast beginning at 4:30 p.m. Eastern time on Wednesday, March 1,
2017.
Conference Call & Webcast Information
WHEN: Wednesday, March 1, 2017, 4:30 p.m. Eastern time.DOMESTIC
DIAL-IN: (866)
634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454 PASSCODE: 80392791WEBCAST:
http://investor.opko.com/events.cfm
For those unable to participate in the live conference call or
webcast, a replay will be available beginning March 1, 2017 two
hours after the close of the conference call. To access the replay,
dial (855) 859-2056 or (404) 537-3406. The replay passcode is:
80392791. The replay can be accessed for a period of time on OPKO’s
website at http://investor.opko.com/events.cfm.
About OPKO Health, Inc.OPKO Health is a
diversified healthcare company that seeks to establish
industry-leading positions in large, rapidly growing markets. Our
diagnostics business includes Bio-Reference Laboratories, the
nation’s third-largest clinical laboratory with a core genetic
testing business and a 400-person sales and marketing team to drive
growth and leverage new products, including the 4Kscore® prostate
cancer test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (launched in November 2016), VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched
by partner TESARO and IV formulation pending FDA approval), TT401,
a once or twice weekly oxyntomodulin for type 2 diabetes and
obesity which is a clinically advanced drug candidate among the new
class of GLP-1 glucagon receptor dual agonists, and TT701, an
androgen receptor modulator for androgen deficiency indications.
Our biologics business includes hGH-CTP, a once weekly human growth
hormone injection (in phase 3 and partnered with Pfizer), a
long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We
also have production and distribution assets worldwide, multiple
strategic investments and an active business development strategy.
More information available at www.opko.com.
Contacts:
OPKO Health, Inc.
David Malina, 305-575-4137
dmalina@opko.com
Investor Relations
Or
Bio-Reference
Tara MacCay, 305-5754195
Tmackay@bioreference.com
Media
Rooney & Associates
Terry Rooney, 212-223-0689
trooney@rooneyco.com
Or
Marion Janic, 212-223-4017
mjanic@rooneyco.com
Investors
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
Or
Bruce Voss, 310-691-7100
bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024